Sunday, June 26, 2022

CRSP (CRISPR Therapeutics AG) may reap gains as insiders became active recently

CRISPR Therapeutics AG’s filing revealed that its Chief Financial Officer TOMSICEK MICHAEL JOHN unloaded Company’s shares for reported $3.46 million on Aug 06. In the deal valued at $138.52 per share,25,000 shares were sold. As a result of this transaction, TOMSICEK MICHAEL JOHN now holds 1,891 shares worth roughly $ 0.12 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, Kulkarni Samarth sold 28,500 shares, generating $3,675,939 in total proceeds. Upon selling the shares at $128.98, the Chief Executive Officer now owns 187,719 shares.

Before that, Kulkarni Samarth sold 1,500 shares. CRISPR Therapeutics AG shares valued at $187,530 were divested by the Chief Executive Officer at a price of $125.02 per share. As a result of the transaction, Kulkarni Samarth now holds 187,719 shares, worth roughly $12.14 million.

While this happened, BMO Capital Markets initiated its CRISPR Therapeutics AG [CRSP] rating to an Outperform in a research note published on Tuesday, June 17, 2022; the price target was $98. PT values the company’s stock at a premium of 34.01 to its Tuesday closing price. A number of analysts have revised their coverage, including Credit Suisse’s analysts, who began to cover the stock in late April with a ‘”a Neutral”‘ rating. Cowen began covering CRSP with a “Market perform” recommendation on December 07, 2021. SVB Leerink started covering the stock on October 19, 2021. It rated CRSP as “an Outperform”.

Price Performance Review of CRSP

On Tuesday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -7.61% to $64.67. On the same session, the stock had its day’s lowest price of $59.82, but rose to a high of $75.24. Over the last five days, the stock has gained 17.01%. CRISPR Therapeutics AG shares have fallen nearly -14.66% since the year began. Nevertheless, the stocks have fallen -50.11% over the past one year. While a 52-week high of $169.76 was reached on 01/03/22, a 52-week low of $42.51 was recorded on 05/12/22. SMA at 50 days reached $57.31, while 200 days put it at $74.61. A total of 7.42 million shares were traded, compared to the trading of 2.41 million shares in the previous session.

Levels Of Support And Resistance For CRSP Stock

The 24-hour chart illustrates a support level at 57.91, which if violated will result in even more drops to 51.16. On the upside, there is a resistance level at 73.33. A further resistance level may holdings at 82.00. The Relative Strength Index (RSI) on the 14-day chart is 54.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.08, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 48.73%. Stochastics %K at 67.38% indicates the stock is a holding.

CRISPR Therapeutics AG [CRSP] – Who Are The Largest Shareholders?

In filings from ARK Investment Management LLC, it is revealed that the company now owns 9,404,071 shares, or roughly 12.14% of the outstanding CRSP shares. In other words, the investor’s shares have risen by 316,203 from its previous 13-F filing of 9087868.0. Additionally, Nikko Asset Management Americas, increased 6.95% of its stake after which the total value it holdings stand at $268,176,313, while Capital Research & Management Co added 0.31% of its stake to hold $209.1 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 1,031,971 shares of CRISPR Therapeutics AG, while Loomis, Sayles & Co. LP bought -25,218 shares. At present, Fidelity Management & Research Co is holding 1,261,622 shares valued at $73.24 million. The Vanguard Group, Inc. owned 1,170,336 shares of the company at the time of its most recent 13F filing, worth $67.94 million.

According to FactSet, CRISPR Therapeutics AG’s share price will average $115.96 in the next year, based on opinions of analysts polled by the firm. This is up nearly 60.0 percent from its previous closing price of $70.00. Analysts expect CRISPR Therapeutics AG stock to reach the higher price of $220.00, while the lowest price estimate is $46.00. However, 28 analysts have rated CRSP stock as an Overweight in their predictions for 2022.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam